[ad_1]
(MedPage Today) — The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from $1.6 billion to $5.8 billion, survey data showed.
Based on an unweighted sample of nearly…
[ad_2]
Source link : https://www.medpagetoday.com/endocrinology/obesity/114904
Author :
Publish date : 2025-03-31 21:00:00
Copyright for syndicated content belongs to the linked Source.
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
Related Posts
